US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 21:30:43 Source:travelViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Analysis: Larson enters conversation with Verstappen as best drivers in the world
Next:Rays opening
You may also like
- A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
- The UK pledges $620 million in new military aid for Ukraine
- Sam Taylor
- Spain reopens a probe into a Pegasus spyware case after a French request to work together
- Lynn Williams breaks NWSL goal
- Mel B details her five
- Lottie Moss sends temperatures soaring in red semi
- North Carolina legislature reconvenes to address budget, vouchers as big elections approach
- Germany's foreign minister visits Kyiv as Ukraine battles to hold off a Russian offensive